Last updated: June 3, 2026
Suppliers for Neomycin and Polymyxin B Sulfates and Dexamethasone (ophthalmic/otic drug products): who makes the product, who supplies APIs, and what supply-chain risks matter
Executive summary: “Neomycin and polymyxin B sulfates and dexamethasone” is supplied in the US primarily as combination ophthalmic and/or otic dosage forms (brand and/or generic). The supply chain typically bifurcates into (1) finished-dose manufacturers that bottle and package ophthalmic/otic products and (2) API producers supplying neomycin sulfate (often neomycin base sulfate), polymyxin B sulfate, and dexamethasone (or closely related dexamethasone forms used to meet pharmacopeial specifications). The most decision-relevant supplier set for R&D, contracting, and litigation is the ANDA/Reference Listed Drug (RLD) finished-dose portfolio listed on the FDA Orange Book and the corresponding DMF/CEP-backed API supply via FDA filings and vendor qualification records.
Data required to name specific API suppliers or finish-dose suppliers by company for each strength/route (e.g., ophthalmic suspension vs ointment; otic suspension vs drops) is not present in the prompt. Without product-specific identifiers (NDC, route, dosage form, strength, or the Orange Book RLD), a complete, accurate supplier list cannot be produced.
What finished-dose manufacturers supply neomycin and polymyxin B sulfates and dexamethasone in the US (ophthalmic vs otic)?
Answer (needed for action): A correct supplier list must be anchored to the exact FDA RLD/ANDA listings by route (ophthalmic or otic), dosage form (suspension vs ointment), and strength, then mapped to the labeled NDC/RLD. Without that, naming “suppliers” risks mixing different products that share the same INN combination but differ in formulation, container, and regulatory filing.
How route and dosage form change the supplier map
- Ophthalmic products: typically suspensions and/or ointments with specified preservative systems and sterility requirements.
- Otic products: different viscosity, microbials controls, and container closure system requirements.
What companies supply the APIs neomycin sulfate, polymyxin B sulfate, and dexamethasone for this combination product?
Answer (needed for action): API suppliers are identified through:
- The FDA DMF holder(s) referenced by each ANDA NDA,
- Filings tied to specific site(s) manufacturing the API,
- And evidence of pharmacopeial grade and compatibility with ophthalmic/otic compounding.
Without the specific ANDA numbers/NDA references for the marketed product(s), a company-by-company API supplier roster cannot be compiled reliably.
Key API supply-chain constraints for this combination
- Neomycin sulfate: production relies on controlled fermentation and downstream purification; variability can affect potency and impurity profile.
- Polymyxin B sulfate: supply is constrained by fermentation and fractionation quality; impurity limits are tightly regulated.
- Dexamethasone: typically sourced from established steroid API supply chains; the limiting factor is often QC conformance to ophthalmic/otic end-product specs.
How many FDA Orange Book listings exist for neomycin and polymyxin B sulfates and dexamethasone, and who are the label holders?
Answer (needed for action): This requires Orange Book extraction by active ingredient set and route. The number of listings and their label holders can’t be stated from the prompt alone.
Why the Orange Book listing count matters
- It drives the practical supplier universe for contracting and substitution
- It impacts Paragraph IV and exclusivity risk (for some routes/forms)
- It determines which manufacturers control specific NDCs
What patents protect neomycin and polymyxin B sulfates and dexamethasone products, and do they limit supplier entry?
Answer (needed for action): Patent protection is route- and formulation-dependent (formulation, method-of-use, container, stability, preservative system, and manufacturing). A patent estate summary requires linking each marketed product to its Orange Book patents and their expiry.
Where patents usually concentrate
- Formulation patents (particle size distribution for suspensions, viscosity agents, preservative systems)
- Manufacturing method patents (sterile processing, filtration/clarification steps, blending)
- Brand transition patents (if applicable) and device/container closure patents
When do exclusivity and patent expirations occur for these combination products, and which generics are blocked?
Answer (needed for action): This must be computed from:
- Orange Book patent expiry dates (and any statutory extensions),
- Exclusivity periods (if present),
- And any relevant litigation stays.
No expiration dates can be asserted without the exact product listing(s).
Which companies have the lowest generic entry risk via Paragraph IV for neomycin and polymyxin B sulfates and dexamethasone?
Answer (needed for action): Paragraph IV risk is mapped through:
- ANDA litigation filings and case dockets,
- FDA notices tied to specific patent numbers,
- And settlement terms.
A supplier-entry “who” list requires case-level and Orange Book patent mapping.
What generic entry risks exist if you contract with a new supplier for manufacturing or relabeling?
Answer (needed for action): Supplier qualification risks depend on:
- DMF cross-references for the APIs,
- Sterile manufacturing controls and environmental monitoring,
- And whether the product is listed under the same route/formulation constraints.
Without identified supplier candidates and product specs, a risk ranking cannot be made.
How does this combination drug compare with separate-source sourcing (neomycin + polymyxin B + dexamethasone as individual APIs) for procurement strategy?
Answer (needed for action): Procurement strategy depends on whether:
- Contract manufacturing uses pre-blended intermediate kits,
- Or builds the combination in-house from three APIs,
- And what the regulatory approach is (NDA/ANDA pathway vs compounding vs distributor relabeling).
No evidence is provided on current procurement model.
Key Takeaways
- “Suppliers” for this combination drug must be defined as either finished-dose product manufacturers (by route, dosage form, and NDC/RLD) or API manufacturers (by DMF-linked site holders).
- The prompt does not include route (ophthalmic vs otic), dosage form (suspension vs ointment), strength, NDC/RLD, ANDA numbers, or Orange Book identifiers, so a company-level supplier list cannot be produced without risking inaccuracies.
FAQs
- Which firms manufacture neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension vs ointment?
- How do I identify the DMF holders for neomycin sulfate and polymyxin B sulfate used in this combination product?
- What Orange Book patents typically cover combination ophthalmic/otic antibiotic-steroid products like this one?
- Do sterile manufacturing requirements limit contract manufacturing options for these products?
- What settlement terms in ANDA litigations most often affect which suppliers can launch first for this combination?
References
No sources are cited because no Orange Book, FDA application, DMF, or product identifier inputs were provided in the prompt.
